Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura
Public ClinicalTrials.gov record NCT00449540. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III Randomized Double-Blind Parallel Group Sham-Controlled Study Evaluating the Efficacy and Safety of Non-invasive Non-repetitive Transcranial Magnetic Stimulation (TMS) for the Acute Preemptive Treatment of the Aura Phase of Migraine Headache
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Assess safety and efficacy of Transcranial Magnetic Stimulation (TMS) for the treatment of migraine with aura The hypothesis is that TMS treatments delivered to the occipital cortex of the brain can stop or interrupt the spreading cortical brain activity that causes or contributes to the migraine headache. Two TMS treatments at an intensity of \<1 Tesla for \~500 microseconds, approximately 30 seconds apart, may stop the aura and prevent the subsequent headache.
Study identification
- NCT ID
- NCT00449540
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 201 participants
Conditions and interventions
Conditions
Interventions
Device
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2006
- Primary completion
- Dec 31, 2007
- Completion
- Feb 29, 2008
- Last update posted
- Aug 14, 2011
2006 – 2008
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| San Francisco Headache Clinic | San Francisco | California | 94109 | — |
| Mile High Research Center | Denver | Colorado | 80218 | — |
| Diamond Headache Clinic, LTD | Chicago | Illinois | 60614 | — |
| Michigan Head Pain & Neurological Institute | Ann Arbor | Michigan | 48104 | — |
| Westside Family Medical Center | Kalamazoo | Michigan | 49009 | — |
| Clinvest, Inc. | Springfield | Missouri | 65807 | — |
| Mercy Health Research | St Louis | Missouri | 63141 | — |
| Kirchner Headache Clinic | Omaha | Nebraska | 68144 | — |
| Montefiore Headache Center | The Bronx | New York | 10461 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Jefferson Headache Center | Philadelphia | Pennsylvania | 19107 | — |
| Nashville Neuroscience Group | Nashville | Tennessee | 37203 | — |
| The Innovative Clinical Research Center | Alexandria | Virginia | 22304 | — |
| Swedish Headache Center | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00449540, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2011 · Synced Sep 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00449540 live on ClinicalTrials.gov.